Business
CalciMedica is a clinical-stage biopharma company developing CRAC channel inhibitors for serious inflammatory and immunologic illnesses.
CalciMedica had no FY2025 revenue row, a wider $29.6M net loss, flat cash burn, negative equity, and a clear insider purchase cluster.
The read at a glance✓ Audited against SEC data
- Business mix — CRAC inhibitor biotechNote
- Revenue — No revenue rowNote
- Net income — Loss $29.6M, worseWatch
- FCF — -$21.2M, flatWatch
- Insiders — 19 purchases / 1 saleOK
- Accounting — Forensic screen unavailableNote
- Balance — Equity -$6.6MWatch
Leadership changes
From CalciMedica, Inc.'s own filings, the day they're filed.
- Fred Middleton · directors · departureeff. 2026-07-02
- Eric Bjerkholt · member of the board of directors · departureeff. 2025-01-15
- Alan Glicklich · director · appointmenteff. 2025-01-13
Latest filings
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-08-27
- 8-K · Company announcement2026-08-20
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CalciMedica, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.